Get the Stockscreener App
24.43
9.42%
-2.54
After Hours:
24.90
0.47
+1.92%
Palvella Therapeutics Inc stock is traded at $24.43, with a volume of 79,817.
It is down -9.42% in the last 24 hours and up +24.96% over the past month.
See More
Previous Close:
$26.97
Open:
$25
24h Volume:
79,817
Relative Volume:
1.31
Market Cap:
$274.14M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-12.00%
1M Performance:
+24.96%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$24.00
$26.39
1-Week Range:
$23.42
$28.78
52-Week Range:
$11.17
$29.27
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Name
Palvella Therapeutics Inc
Sector
Industry
Phone
(484) 253-1461
Address
125 STRAFFORD AVE, WAYNE
Compare PVLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
24.43 | 274.14M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-25 | Initiated | Stifel | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-20-25 | Initiated | Canaccord Genuity | Buy |
| Feb-05-25 | Initiated | TD Cowen | Buy |
| Dec-26-24 | Initiated | H.C. Wainwright | Buy |
| Dec-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-30-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-19 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Initiated | Jefferies | Buy |
| Jan-16-18 | Reiterated | H.C. Wainwright | Buy |
| May-30-17 | Initiated | Rodman & Renshaw | Buy |
| Aug-05-16 | Resumed | ROTH Capital | Buy |
| Aug-12-15 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-15 | Initiated | Oppenheimer | Outperform |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
View All
Palvella Therapeutics Inc Stock (PVLA) Latest News
Palvella Therapeutics Announces Late-Breaking Presentation at Global Pediatric Dermatology Congress - MSN
Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology - The Manila Times
Groundbreaking Phase 3 Results: First-Ever Treatment for Rare Lymphatic Disease Heads to Major Congress - Stock Titan
Palvella Therapeutics (NASDAQ:PVLA) Given “Buy” Rating at HC Wainwright - Defense World
Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo
Is Palvella Therapeutics Inc. (PVLA) the Best Performing NASDAQ Stock So Far in 2025? - Insider Monkey
Stifel maintains $45 target on Palvella Therapeutics stock By Investing.com - Investing.com Canada
Stifel maintains $45 target on Palvella Therapeutics stock - Investing.com
Earnings call transcript: Palvella Therapeutics Q4 2024 reveals strategic focus By Investing.com - Investing.com South Africa
Earnings call transcript: Palvella Therapeutics Q4 2024 reveals strategic focus - Investing.com
Palvella Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Palvella Therapeutics Reports 2024 Financial Results and Updates - TipRanks
PALVELLA THERAPEUTICS, INC. SEC 10-K Report - TradingView
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Palvella Therapeutics to Announce 2024 Financial Results and Host Investor Call on March 31, 2025 - MSN
Palvella Therapeutics (PVLA) to Release Earnings on Monday - Defense World
Palvella Therapeutics Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
Brokerages Set Palvella Therapeutics (NASDAQ:PVLA) Price Target at $43.20 - Defense World
Palvella Therapeutics (PVLA) Projected to Post Earnings on Monday - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Stifel Nicolaus - Defense World
Is Palvella Therapeutics (PVLA) the Best Performing Stock So Far in 2025? - Insider Monkey
Stifel Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
Stifel Initiates Palvella Therapeutics at Buy With $45 Price Target - MarketScreener
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Jones Trading - Defense World
Stifel analysts initiate Palvella Therapeutics stock with Buy, $45 target By Investing.com - Investing.com Canada
Jones Trading Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
Stifel initiates Palvella Therapeutics with a buy, $45 target By Investing.com - Investing.com Canada
Stifel analysts initiate Palvella Therapeutics stock with Buy, $45 target - Investing.com
Stifel initiates Palvella Therapeutics with a buy, $45 target - Investing.com
Palvella Therapeutics initiated with a Buy at Stifel - TipRanks
Palvella Therapeutics (PVLA) Projected to Post Earnings on Thursday - Defense World
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025 - GlobeNewswire
Palvella Therapeutics, Inc. Scheduled to Report Full Year 2024 Financial Results on March 31, 2025 - Nasdaq
Rare Disease Leader Palvella Therapeutics Unveils 2024 Financial Performance March 31 - StockTitan
Lucid Capital sets $49 target on Palvella Therapeutics stock By Investing.com - Investing.com UK
Individual investors who hold 41% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gained 12%, insiders profited as well - Yahoo Finance
Palvella Therapeutics Insider Confidence Rewarded, Stock Hits US$308m Market Cap - simplywall.st
Pieris Pharmaceuticals stock soars to 52-week high of $29.01 - Investing.com
PavellaUndiscovered Biotechnology Stock - TradingView
PalvellaUndiscovered Biotechnology Stock - Barchart
Palvella Therapeutics (NASDAQ:PVLA) Coverage Initiated at Scotiabank - Defense World
Scotiabank Initiates Coverage of Palvella Therapeutics (PVLA) with Sector Outperform Recommendation - Nasdaq
Scotiabank sets Palvella stock to Sector Outperform, $50 target - Investing.com
Scotiabank sets Palvella stock to Sector Outperform, $50 target By Investing.com - Investing.com UK
Palvella Therapeutics initiated with an Outperform at Scotiabank - TipRanks
Pieris Pharmaceuticals stock hits 52-week high at $22.56 By Investing.com - Investing.com Canada
Pieris Pharmaceuticals stock hits 52-week high at $22.56 - Investing.com
Palvella Therapeutics Enhances Investor Relations with New Presentation - TipRanks
Why Palvella Therapeutics, Inc. (PVLA) is Skyrocketing So Far in 2025 - MSN
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Palvella Therapeutics Inc Stock (PVLA) Financials Data
There is no financial data for Palvella Therapeutics Inc (PVLA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):